top of page
  • Recruiting

NCT05243797: Phase 3: EMN 30 - Tec + Len Vs Len Alone NDMM as Maint. Therapy Post ASCT (MajesTEC-4)

Updated: Oct 24, 2022

EMN30 - MajesTEC-4

64007957MMY3003

MajesTEC-4 TECLISTAMAB MYELOMA TRIAL emn30

NCT05243797: Phase 3: Teclistamab + Lenalidomide Versus Lenalidomide Alone in NDMM Myeloma as Maintenance Therapy Post ASCT (MajesTEC-4)


A Study of Teclistamab in Combination With Lenalidomide Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation (MajesTEC-4)

ClinicalTrials.gov Identifier: NCT05243797


This is a multicenter, randomized, open-label, Phase 3 study in participants with newly diagnosed multiple myeloma to evaluate the benefits of teclistamab in combination with lenalidomide versus lenalidomide alone as maintenance therapy after autologous stem cell transplant.

 

Sponsor

European Myeloma Network


Collaborator

Janssen Pharmaceutical


Multiple Locations

International Study

Europe

 

ClinicalTrials.gov Identifier: NCT05243797

Official Title: Phase 3 Study of Teclistamab in Combination With Lenalidomide Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

First Posted : February 17, 2022

Click here to see details on ClinicalTrials.gov


The European Myeloma Network

https://www.myeloma-europe.org/


EU Clinical Trials Register

Click here for details

 

JNJ 64007957 - Teclistamab

 

Drug: Teclistamab

Drug: Lenalidomide

 

Locations


Australia


Europe

United Kingdom

Italy

Netherlands

Germany

Austria

Belgium

Czechia

Denmark

Greece

Norway

Serbia

Switzerland

Turkey

 

RELATED POSTS


TECLISTAMAB STUDIES:


NCT03145181: Phase 1 - Teclistamab, Humanized BCMA*CD3 Bispecific Ab, in Relapsed Myeloma (MajesTEC1)

Click here for details


NCT04557098: Phase 2- Teclistamab, in Participants With Relapsed or Refractory Myeloma (MajesTEC-1)

Click here for details


NCT05083169: Phase 3 - Tec-Dara Vs DPd Vs DVd in Relapsed or Refractory Myeloma - (MajesTEC-3)

Click here for details


NCT04722146: Phase 1b - Teclistamab With Other Anticancer Therapies in Participants With Myeloma

Click here for details


NCT05231629: Phase 2: Sequential Therapy in Multiple Myeloma Guided by MRD Assessments (MASTER-2)

Click here for details

 

TALQUETAMAB STUDIES:


NCT03399799: Phase 1 - Talquetamab, a Humanized GPRC5D x CD3 Bis Ab - Ref MM - MonumenTAL-1

Click here for details


NCT04634552: Phase 2 - A Study of Talquetamab in Participants With Refractory Multiple Myeloma

Click here for details


NCT05050097: Phase 1 - A Study of Talquetamab With Other Anticancer Therapies in Multiple Myeloma

Click here for details


NCT04773522: Phase 1 - JNJ-64407564 in Japanese Participants With Relapsed or Refractory Myeloma

Click here for details

 

TECLISTAMAB AND TALQUETAMAB STUDIES:


NCT04586426: Phase 1b - Talquetamab and Teclistamab in Relapsed or Refractory Multiple Myeloma

Click here for details


NCT04108195: Phase 1b - Subcutaneous Dara With Bispecific T Cell Redirection Antibodies - TRIMM-2

Click here for details






Posts Archive